242 related articles for article (PubMed ID: 32704014)
1. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
Kim KJ; Kim JW; Sung JH; Suh KJ; Lee JY; Kim SH; Lee JO; Kim JW; Kim YJ; Kim JH; Bang SM; Lee JS; Kim HK; Lee KW
Sci Rep; 2020 Jul; 10(1):12308. PubMed ID: 32704014
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
Bhattacharya B; Akram M; Balasubramanian I; Tam KK; Koh KX; Yee MQ; Soong R
Cancer Biol Ther; 2012 Jan; 13(1):34-42. PubMed ID: 22336586
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
4. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Bonelli MA; Cavazzoni A; Saccani F; Alfieri RR; Quaini F; La Monica S; Galetti M; Cretella D; Caffarra C; Madeddu D; Frati C; Lagrasta CA; Falco A; Rossetti P; Fumarola C; Tiseo M; Petronini PG; Ardizzoni A
Mol Cancer Ther; 2015 Aug; 14(8):1916-27. PubMed ID: 26013318
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.
Shu S; Yamashita-Kashima Y; Yanagisawa M; Nakanishi H; Kodera Y; Harada N; Yoshimura Y
Anticancer Drugs; 2020 Mar; 31(3):241-250. PubMed ID: 31633500
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma.
Tsuchihashi H; Naruse T; Yanamoto S; Okuyama K; Furukawa K; Omori K; Umeda M
Oncol Rep; 2020 Sep; 44(3):863-872. PubMed ID: 32705230
[TBL] [Abstract][Full Text] [Related]
8. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
9. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
Jacquemetton J; Kassem L; Poulard C; Dahmani A; De Plater L; Montaudon E; Sourd L; Morisset L; El Botty R; Chateau-Joubert S; Vacher S; Bièche I; Treilleux I; Trédan O; Marangoni E; Le Romancer M
Breast Cancer Res; 2021 May; 23(1):57. PubMed ID: 34020697
[TBL] [Abstract][Full Text] [Related]
10. EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.
Piper AK; Penney C; Holliday J; Tincknell G; Ma Y; Napaki S; Pantel K; Brungs D; Ranson M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791602
[TBL] [Abstract][Full Text] [Related]
11. Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines.
Holzhauser S; Lukoseviciute M; Papachristofi C; Vasilopoulou C; Herold N; Wickström M; Kostopoulou ON; Dalianis T
Int J Oncol; 2021 Feb; 58(2):211-225. PubMed ID: 33491755
[TBL] [Abstract][Full Text] [Related]
12. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
13. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
Wei Y; Lin S; Zhi W; Chu T; Liu B; Peng T; Xu M; Ding W; Cao C; Wu P
J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
[TBL] [Abstract][Full Text] [Related]
14. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
Kang SK; Bae HJ; Kwon WS; Kim TS; Kim KH; Park S; Yu SY; Hwang J; Park J; Chung HC; Rha SY
Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
Yan C; Yang J; Saleh N; Chen SC; Ayers GD; Abramson VG; Mayer IA; Richmond A
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069042
[TBL] [Abstract][Full Text] [Related]
17. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
[TBL] [Abstract][Full Text] [Related]
18. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
[TBL] [Abstract][Full Text] [Related]
19. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
[TBL] [Abstract][Full Text] [Related]
20. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
